56 related articles for article (PubMed ID: 35247920)
1. Targeted Analysis of Cell-free Circulating Tumor DNA is Suitable for Early Relapse and Actionable Target Detection in Patients with Neuroblastoma.
Lodrini M; Graef J; Thole-Kliesch TM; Astrahantseff K; Sprüssel A; Grimaldi M; Peitz C; Linke RB; Hollander JF; Lankes E; Künkele A; Oevermann L; Schwabe G; Fuchs J; Szymansky A; Schulte JH; Hundsdörfer P; Eckert C; Amthauer H; Eggert A; Deubzer HE
Clin Cancer Res; 2022 May; 28(9):1809-1820. PubMed ID: 35247920
[TBL] [Abstract][Full Text] [Related]
2. Sequential analysis of cfDNA reveals clonal evolution in neuroblastoma patients receiving ALK targeted therapy.
Bobin C; Iddir Y; Butterworth C; Masliah-Planchon J; Saint-Charles A; Bellini A; Bhalshankar J; Pierron G; Combaret V; Attignon V; André N; Corradini N; Dumont B; Mansuy L; Khanfar C; Klein S; Briandet C; Plantaz D; Millot F; Thouvenin S; Aerts I; Ndounga-Diakou LA; Laghouati S; Abbou S; Jehanno N; Tissot H; Renault S; Baulande S; Raynal V; Bozec L; Bieche I; Delattre O; Berlanga P; Schleiermacher G
Clin Cancer Res; 2024 May; ():. PubMed ID: 38787533
[TBL] [Abstract][Full Text] [Related]
3. Neuroblastoma Molecular Risk-Stratification of DNA Copy Number and
Kahana-Edwin S; Cain LE; McCowage G; Darmanian A; Wright D; Mullins A; Saletta F; Karpelowsky J
Cancers (Basel); 2021 Jul; 13(13):. PubMed ID: 34282791
[TBL] [Abstract][Full Text] [Related]
4. Intrinsic susceptibility MRI identifies tumors with ALKF1174L mutation in genetically-engineered murine models of high-risk neuroblastoma.
Jamin Y; Glass L; Hallsworth A; George R; Koh DM; Pearson AD; Chesler L; Robinson SP
PLoS One; 2014; 9(3):e92886. PubMed ID: 24667968
[TBL] [Abstract][Full Text] [Related]
5. Serial Profiling of Circulating Tumor DNA Identifies Dynamic Evolution of Clinically Actionable Genomic Alterations in High-Risk Neuroblastoma.
Bosse KR; Giudice AM; Lane MV; McIntyre B; Schürch PM; Pascual-Pasto G; Buongervino SN; Suresh S; Fitzsimmons A; Hyman A; Gemino-Borromeo M; Saggio J; Berko ER; Daniels AA; Stundon J; Friedrichsen M; Liu X; Margolis ML; Li MM; Tierno MB; Oxnard GR; Maris JM; Mossé YP
Cancer Discov; 2022 Dec; 12(12):2800-2819. PubMed ID: 36108156
[TBL] [Abstract][Full Text] [Related]
6. Adrenergic and mesenchymal signatures are identifiable in cell-free DNA and correlate with metastatic disease burden in children with neuroblastoma.
Vayani OR; Kaufman ME; Moore K; Chennakesavalu M; TerHaar R; Chaves G; Chlenski A; He C; Cohn SL; Applebaum MA
Pediatr Blood Cancer; 2024 Jan; 71(1):e30735. PubMed ID: 37859597
[TBL] [Abstract][Full Text] [Related]
7. Clinical trial inclusion in patients with relapsed/refractory neuroblastoma following the European Precision Cancer Medicine trial MAPPYACTS.
Chaix J; Schleiermacher G; Corradini N; André N; Thebaud E; Gambart M; Defachelles AS; Entz-Werle N; Chastagner P; De Carli É; Ducassou S; Landman-Parker J; Adam-de-Beaumais T; Larive A; Michiels S; Vassal G; Valteau-Couanet D; Geoerger B; Berlanga P
Eur J Cancer; 2024 Apr; 201():113923. PubMed ID: 38377775
[TBL] [Abstract][Full Text] [Related]
8. Classification of Brain Tumors by Nanopore Sequencing of Cell-Free DNA from Cerebrospinal Fluid.
Afflerbach AK; Rohrandt C; Brändl B; Sönksen M; Hench J; Frank S; Börnigen D; Alawi M; Mynarek M; Winkler B; Ricklefs F; Synowitz M; Dührsen L; Rutkowski S; Wefers AK; Müller FJ; Schoof M; Schüller U
Clin Chem; 2024 Jan; 70(1):250-260. PubMed ID: 37624932
[TBL] [Abstract][Full Text] [Related]
9. Isolation and Characterization of Cell-Free DNA from Cerebral Organoids.
Silver BB; Brooks A; Gerrish K; Tokar EJ
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791569
[TBL] [Abstract][Full Text] [Related]
10. Adrenergic and mesenchymal signatures are identifiable in cell-free DNA and correlate with metastatic disease burden in children with neuroblastoma.
Vayani OR; Kaufman ME; Moore K; Chennakesavalu M; TerHaar R; Chaves G; Chlenski A; He C; Cohn SL; Applebaum MA
bioRxiv; 2023 Sep; ():. PubMed ID: 37693610
[TBL] [Abstract][Full Text] [Related]
11. Circulating free DNA and its potential in the diagnostics and therapy of malignant lymphoma.
Hricko S; Navrkalová V; Janíková A
Klin Onkol; 2023; 37(4):273-280. PubMed ID: 38195381
[TBL] [Abstract][Full Text] [Related]
12. Detection of neuron-derived cfDNA in blood plasma: a new diagnostic approach for neurodegenerative conditions.
Pollard C; Aston K; Emery BR; Hill J; Jenkins T
Front Neurol; 2023; 14():1272960. PubMed ID: 38020656
[TBL] [Abstract][Full Text] [Related]
13. Bisulfite Amplicon Sequencing Can Detect Glia and Neuron Cell-Free DNA in Blood Plasma.
Chatterton Z; Mendelev N; Chen S; Carr W; Kamimori GH; Ge Y; Dwork AJ; Haghighi F
Front Mol Neurosci; 2021; 14():672614. PubMed ID: 34276305
[TBL] [Abstract][Full Text] [Related]
14. 5-Hydroxymethylcytosine Profiling of Cell-Free DNA Identifies Bivalent Genes That Are Prognostic of Survival in High-Risk Neuroblastoma.
Chennakesavalu M; Moore K; Chaves G; Veeravalli S; TerHaar R; Wu T; Lyu R; Chlenski A; He C; Piunti A; Applebaum MA
JCO Precis Oncol; 2024 Jan; 8():e2300297. PubMed ID: 38295320
[TBL] [Abstract][Full Text] [Related]
15. Case series on clinical applications of liquid biopsy in pediatric solid tumors: towards improved diagnostics and disease monitoring.
Gelineau NU; van Barneveld A; Samim A; Van Zogchel L; Lak N; Tas ML; Matser Y; Mavinkurve-Groothuis AMC; van Grotel M; Zsiros J; van Eijkelenburg NKA; Knops RRG; van Ewijk R; Langenberg KPS; Krijger R; Hiemcke-Jiwa LS; Van Paemel R; Cornelli L; De Preter K; De Wilde B; Van Der Schoot E; Tytgat G
Front Oncol; 2023; 13():1209150. PubMed ID: 37664065
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of circulating tumor DNA by electropherogram analysis and methylome profiling in high-risk neuroblastomas.
Trinidad EM; Juan-Ribelles A; Pisano G; Castel V; Cañete A; Gut M; Heath S; Font de Mora J
Front Oncol; 2023; 13():1037342. PubMed ID: 37251933
[TBL] [Abstract][Full Text] [Related]
17. Somatic Copy Number Alteration in Circulating Tumor DNA for Monitoring of Pediatric Patients with Cancer.
Ruas JS; Silva FLT; Euzébio MF; Biazon TO; Daiggi CMM; Nava D; Franco MT; Cardinalli IA; Cassone AE; Pereira LH; Seidinger AL; Maschietto M; Jotta PY
Biomedicines; 2023 Apr; 11(4):. PubMed ID: 37189699
[TBL] [Abstract][Full Text] [Related]
18. Targeted locus amplification to develop robust patient-specific assays for liquid biopsies in pediatric solid tumors.
van Zogchel LMJ; Lak NSM; Gelineau NU; Sergeeva I; Stelloo E; Swennenhuis J; Feitsma H; van Min M; Splinter E; Bleijs M; Groot Koerkamp M; Breunis W; Meister MT; Kholossy WH; Holstege FCP; Molenaar JJ; de Leng WWJ; Stutterheim J; van der Schoot CE; Tytgat GAM
Front Oncol; 2023; 13():1124737. PubMed ID: 37152023
[TBL] [Abstract][Full Text] [Related]
19. Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma.
Berko ER; Witek GM; Matkar S; Petrova ZO; Wu MA; Smith CM; Daniels A; Kalna J; Kennedy A; Gostuski I; Casey C; Krytska K; Gerelus M; Pavlick D; Ghazarian S; Park JR; Marachelian A; Maris JM; Goldsmith KC; Radhakrishnan R; Lemmon MA; Mossé YP
Nat Commun; 2023 May; 14(1):2601. PubMed ID: 37147298
[TBL] [Abstract][Full Text] [Related]
20. Cell-Free RNA from Plasma in Patients with Neuroblastoma: Exploring the Technical and Clinical Potential.
Lak NSM; Seijger A; van Zogchel LMJ; Gelineau NU; Javadi A; Zappeij-Kannegieter L; Bongiovanni L; Andriessen A; Stutterheim J; van der Schoot CE; de Bruin A; Tytgat GAM
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
